Works matching IS 03618609 AND DT 2010 AND VI 85 AND IP 3


Results: 24
    1
    2
    3
    4
    5

    Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.

    Published in:
    American Journal of Hematology, 2010, v. 85, n. 3, p. 164, doi. 10.1002/ajh.21615
    By:
    • Lilly, Michael B.;
    • Ottmann, Oliver G.;
    • Shah, Neil P.;
    • Larson, Richard A.;
    • Reiffers, Josy J.;
    • Ehninger, Gerhard;
    • Müller, Martin C.;
    • Charbonnier, Aude;
    • Bullorsky, Eduardo;
    • Dombret, Herve;
    • Brigid Bradley-Garelik, Mary;
    • Zhu, Chao;
    • Martinelli, Giovanni
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24